news

April 12, 2019

Tumor Mutation Burden Study Shows Viability of In-House Testing

As laboratories increasingly look to bring advanced molecular testing in-house, the results of a new retrospective clinical research study show that tumor mutation burden... Read More
April 12, 2019

Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360

Guardant Health, Inc. (Nasdaq: GH), announced that its market leading liquid biopsy, Guardant360®, will be a covered benefit for the members of the health... Read More
April 12, 2019

SomaLogic announces new collaboration with Janssen Research & Development

SomaLogic, Inc. has announced that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies... Read More
April 12, 2019

FH Foundation Expands FIND FH® to Speed Diagnosis of Individuals with Homozygous Familial Hypercholesterolemia

The FH Foundation recently announced the launch of the FIND HoFH program to identify individuals at risk for homozygous familial hypercholesterolemia (HoFH). The goal... Read More
April 12, 2019

SOPHiA GENETICS Achieves CE-IVD Milestone for Its Solid Tumor Solution for Accurate Cancer Detection

SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today the CE-IVD marking of its Solid Tumor Solution (STS), a new step in the fight... Read More
April 3, 2019

PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive Health Management

Today, in collaboration with Helix, PerkinElmer, Inc., a global leader committed to innovating for a healthier world, launched GenePrism: Actionable Insights, a new genetic... Read More
April 3, 2019

Pat Basu, MD, MBA, named President and Chief Executive Officer of Cancer Treatment Centers of America

BOCA RATON, Fla., April 3, 2019 /PRNewswire/ — Pat A. Basu, MD, MBA, an accomplished health care executive and entrepreneur, has been appointed President... Read More
April 3, 2019

Roche launches NAVIFY Mutation Profiler and NAVIFY Therapy Matcher to support comprehensive genomic profiling in cancer

• CE-IVD marked software as a medical device that aids clinicians to more easily interpret NGS oncology tests • Classifies detected variants in accordance... Read More
April 2, 2019

Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing

WALTHAM, Mass. and CAMBRIDGE, Mass., March 24, 2019 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Brammer... Read More
April 2, 2019

Multi-Year Agreement Broadens Uses of Real-World Evidence and Accelerates Precision Oncology Innovations

    Bristol-Myers Squibb and Concerto HealthAI, a market leader in oncology-specific Real-World Data (RWD) and advanced Artificial Intelligence (AI)-enabled insight solutions for Real-World... Read More
January 30, 2019

Scientists Engineer New CRISPR Platform for DNA Targeting

CRISPR team harnesses new Cas12b enzyme for use in eukaryotic cells, adding to the CRISPR toolbox. A team that includes the scientist who first... Read More
January 30, 2019

Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed”

Daiichi Sankyo, Inc. today announced a partnership with dancer, choreographer and TV host Carrie Ann Inaba on Get Iron Informed, a campaign to raise... Read More
January 30, 2019

New Study to Focus on Unique Needs of Acute Myeloid Leukemia Patients

The Cancer Support Community (CSC), a global nonprofit, is launching a unique research study focused on individuals diagnosed with Acute Myeloid Leukemia (AML), a... Read More
January 30, 2019

PHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher Scientific

PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) has announced that it has signed a definitive agreement with Thermo Fisher Scientific Inc. (NYSE: TMO,... Read More
January 30, 2019

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2018. Fourth quarter 2018 results: Revenue of $867... Read More
MORE NEWS